Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd
- PMID: 28276304
- DOI: 10.1080/14760584.2017.1294068
Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd
Abstract
Rabies is a 100% fatal disease with significant disease burden in Asia and Africa but preventable with vaccines and immunoglobulins. There are very few WHO prequalified cell culture derived rabies vaccines available globally for use in humans. We have developed a new purified vero cell rabies vaccine (Rabivax-S) to meet this demand. Areas covered: In this review, we have described the detailed manufacturing process of Rabivax-S and summary of preclinical and clinical development based on the data generated in-house. Expert commentary: Rabivax-S has been developed on Vero ATCC CCL81 cells using Pitman Moore (PM3218) strain. Following all the GMP requirements the vaccine was tested in GLP toxicology studies. Further it underwent clinical trials in preexposure and postexposure settings and was found safe and immunogenic.
Keywords: Rabivax-S; immunogenicity; purified vero cell rabies vaccine; rabies; safety.
Similar articles
-
A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes.Vaccine. 2016 Sep 14;34(40):4820-6. doi: 10.1016/j.vaccine.2016.08.005. Epub 2016 Aug 21. Vaccine. 2016. PMID: 27554534 Clinical Trial.
-
An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects.Hum Vaccin. 2008 Jul-Aug;4(4):275-9. doi: 10.4161/hv.4.4.5588. Hum Vaccin. 2008. PMID: 18682695
-
Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers.Vaccine. 2013 May 31;31(24):2719-22. doi: 10.1016/j.vaccine.2013.03.050. Epub 2013 Apr 12. Vaccine. 2013. PMID: 23583817 Clinical Trial.
-
Rabies antibody titers in vaccinees: protection, failure and prospects.Int J Clin Pharmacol Ther Toxicol. 1992 Mar;30(3):107-12. Int J Clin Pharmacol Ther Toxicol. 1992. PMID: 1506120 Review.
-
The statistical analysis of immunogenicity data in vaccine trials. A review of methodologies and issues.Ann N Y Acad Sci. 1995 May 31;754:329-46. doi: 10.1111/j.1749-6632.1995.tb44466.x. Ann N Y Acad Sci. 1995. PMID: 7625669 Review. No abstract available.
Cited by
-
Differential susceptibility & replication potential of Vero E6, BHK-21, RD, A-549, C6/36 cells & Aedes aegypti mosquitoes to three strains of chikungunya virus.Indian J Med Res. 2019 Jun;149(6):771-777. doi: 10.4103/ijmr.IJMR_453_17. Indian J Med Res. 2019. PMID: 31496530 Free PMC article.
-
Infection and Prevention of Rabies Viruses.Microorganisms. 2025 Feb 9;13(2):380. doi: 10.3390/microorganisms13020380. Microorganisms. 2025. PMID: 40005749 Free PMC article. Review.
-
Rhabdoviruses as vectors for vaccines and therapeutics.Curr Opin Virol. 2020 Oct;44:169-182. doi: 10.1016/j.coviro.2020.09.003. Epub 2020 Oct 29. Curr Opin Virol. 2020. PMID: 33130500 Free PMC article. Review.
-
Safety and immunogenicity of an inactivated vero cell-based rabies vaccine (Rabivax-S) in pre-exposure prophylaxis schedule in Vietnam.Clin Exp Vaccine Res. 2025 Jan;14(1):51-58. doi: 10.7774/cevr.2025.14.e9. Epub 2025 Jan 22. Clin Exp Vaccine Res. 2025. PMID: 39927222 Free PMC article.
-
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.Lancet Reg Health Southeast Asia. 2023 May 16;14:100207. doi: 10.1016/j.lansea.2023.100207. eCollection 2023 Jul. Lancet Reg Health Southeast Asia. 2023. PMID: 37492421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
